Missling, Q3 2022 Earnings call:
"So, for the commercialization, we already have, as I mentioned just briefly before, sufficient drug product for the entire commercial rollout of ANAVEX 2-73 in Rett syndrome. The marketing rollout cost as you know when you have an approved drug, your ability to access capital and resources for that is broader than the equity capital market. You have access to debt financing and other financial vehicles which are basically not dilutive. And we certainly will make use of that. So, the cash is -- available, is not limited to equity, which is right now the focus in a stage where the company does not yet have revenue. But this can change very quickly and hopefully very soon that we’re able to expand on the ability to use financial vehicles and resources, which are basically non-dilutive to shareholders."
This was just three months ago (8/9/22). He has no intention of further dilution.
News 
Market Data 
Discover 
